FCGR1A and leukemia: Recently, non‐covalent antibody modification of nanoparticles has been demonstrated as an efficient targeted delivery strategy,[19] and biotin‐avidin affinity is particularly selective.[20] Since anti‐human CD64‐targeting single chain antibody (scFv) was found to be effective in human leukemia cell‐targeted delivery in vivo,[15] anti‐CD64 scFv was recombinantly fused to monomeric avidin[21] (sFVA) for nanoparticle modification (Figure 1a).